Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

We shall overcome (drug resistance) some day.

Sharma GG, Mologni L.

Oncotarget. 2019 Jan 4;10(2):84-85. doi: 10.18632/oncotarget.26550. eCollection 2019 Jan 4. No abstract available.

2.

Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling.

Ceccon M, Mauri M, Massimino L, Giudici G, Piazza R, Gambacorti-Passerini C, Mologni L.

Cancers (Basel). 2018 Dec 12;10(12). pii: E509. doi: 10.3390/cancers10120509.

3.

Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.

Menotti M, Ambrogio C, Cheong TC, Pighi C, Mota I, Cassel SH, Compagno M, Wang Q, Dall'Olio R, Minero VG, Poggio T, Sharma GG, Patrucco E, Mastini C, Choudhari R, Pich A, Zamo A, Piva R, Giliani S, Mologni L, Collings CK, Kadoch C, Gambacorti-Passerini C, Notarangelo LD, Anton IM, Voena C, Chiarle R.

Nat Med. 2019 Jan;25(1):130-140. doi: 10.1038/s41591-018-0262-9. Epub 2018 Dec 3.

PMID:
30510251
4.

Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.

Redaelli S, Ceccon M, Zappa M, Sharma GG, Mastini C, Mauri M, Nigoghossian M, Massimino L, Cordani N, Farina F, Piazza R, Gambacorti-Passerini C, Mologni L.

Cancer Res. 2018 Dec 15;78(24):6866-6880. doi: 10.1158/0008-5472.CAN-18-1867. Epub 2018 Oct 15.

PMID:
30322862
5.

Synergistic activity of dasatinib in combination with β-catenin blockade in colorectal cancer cells.

Mologni L.

Eur J Cancer. 2018 Nov;104:231-232. doi: 10.1016/j.ejca.2018.08.025. Epub 2018 Oct 12. No abstract available.

PMID:
30322680
6.

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.

Mologni L, Costanza M, Sharma GG, Viltadi M, Massimino L, Citterio S, Purgante S, Raman H, Pirola A, Zucchetti M, Piazza R, Gambacorti-Passerini C.

Neoplasia. 2018 May;20(5):467-477. doi: 10.1016/j.neo.2018.02.009. Epub 2018 Mar 30.

7.

β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy.

Saponaro C, Sergio S, Coluccia A, De Luca M, La Regina G, Mologni L, Famiglini V, Naccarato V, Bonetti D, Gautier C, Gianni S, Vergara D, Salzet M, Fournier I, Bucci C, Silvestri R, Passerini CG, Maffia M, Coluccia AML.

Oncogene. 2018 Jun;37(24):3301-3316. doi: 10.1038/s41388-018-0170-y. Epub 2018 Mar 19.

8.

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Sharma GG, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C, Chiarle R.

Cancers (Basel). 2018 Feb 28;10(3). pii: E62. doi: 10.3390/cancers10030062. Review.

9.

Novel targeted therapeutics for MEN2.

Redaelli S, Plaza-Menacho I, Mologni L.

Endocr Relat Cancer. 2018 Feb;25(2):T53-T68. doi: 10.1530/ERC-17-0297. Review.

PMID:
29348306
10.

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer.

Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, Jänne PA, Chiarle R.

Oncotarget. 2017 Sep 23;8(54):92265-92274. doi: 10.18632/oncotarget.21182. eCollection 2017 Nov 3.

11.

Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.

Mologni L, Piazza R, Khandelwal P, Pirola A, Gambacorti-Passerini C.

Am J Hematol. 2017 Oct;92(10):E623-E625. doi: 10.1002/ajh.24865. Epub 2017 Aug 17. No abstract available.

12.

Discovery of wt RET and V804M RET Inhibitors: From Hit to Lead.

Mologni L, Dalla Via M, Chilin A, Palumbo M, Marzaro G.

ChemMedChem. 2017 Aug 22;12(16):1390-1398. doi: 10.1002/cmdc.201700243. Epub 2017 Jul 25.

PMID:
28639308
13.

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition.

Mologni L, Magistroni V, Casuscelli F, Montemartini M, Gambacorti-Passerini C.

J Cancer. 2017 Jan 1;8(1):140-145. doi: 10.7150/jca.15838. eCollection 2017.

14.

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.

Redaelli S, Ceccon M, Antolini L, Rigolio R, Pirola A, Peronaci M, Gambacorti-Passerini C, Mologni L.

Oncotarget. 2016 Nov 8;7(45):72886-72897. doi: 10.18632/oncotarget.12128.

15.

RET kinase inhibitors: a review of recent patents (2012-2015).

Mologni L, Gambacorti-Passerini C, Goekjian P, Scapozza L.

Expert Opin Ther Pat. 2017 Jan;27(1):91-99. Epub 2016 Sep 26. Review.

PMID:
27646564
16.

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.

Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.

Mol Cancer Ther. 2016 Apr;15(4):628-39. doi: 10.1158/1535-7163.MCT-15-0758. Epub 2016 Mar 3.

17.

Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.

Ceccon M, Merlo MEB, Mologni L, Poggio T, Varesio LM, Menotti M, Bombelli S, Rigolio R, Manazza AD, Di Giacomo F, Ambrogio C, Giudici G, Casati C, Mastini C, Compagno M, Turner SD, Gambacorti-Passerini C, Chiarle R, Voena C.

Oncogene. 2016 Jul 21;35(29):3854-3865. doi: 10.1038/onc.2015.456. Epub 2015 Dec 14.

18.

Current and future treatment of anaplastic lymphoma kinase-rearranged cancer.

Mologni L.

World J Clin Oncol. 2015 Oct 10;6(5):104-8. doi: 10.5306/wjco.v6.i5.104.

19.

Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.

Voena C, Menotti M, Mastini C, Di Giacomo F, Longo DL, Castella B, Merlo MEB, Ambrogio C, Wang Q, Minero VG, Poggio T, Martinengo C, D'Amico L, Panizza E, Mologni L, Cavallo F, Altruda F, Butaney M, Capelletti M, Inghirami G, Jänne PA, Chiarle R.

Cancer Immunol Res. 2015 Dec;3(12):1333-1343. doi: 10.1158/2326-6066.CIR-15-0089. Epub 2015 Sep 29.

20.

Expanding the portfolio of anti-ALK weapons.

Mologni L.

Transl Lung Cancer Res. 2015 Feb;4(1):5-7. doi: 10.3978/j.issn.2218-6751.2014.07.02.

Supplemental Content

Loading ...
Support Center